Incontinentia Pigmenti

Mendelian MONDO:0010631 Pathograph 18 Show in embeddings browser Ectodermal Dysplasia X-linked Genodermatosis

Incontinentia pigmenti (IP) is a rare X-linked dominant, typically male-lethal, multisystem ectodermal disorder caused by loss-of-function variants in IKBKG (NEMO), the regulatory subunit of the IKK complex required for canonical NF-kB activation. Loss of NEMO removes the NF-kB-dependent cytoprotective program, so mutant cells become hypersensitive to TNF-induced apoptosis; the selective elimination of cells expressing the mutant X produces extremely skewed X-inactivation (allowing female survival and the mosaic Blaschko-linear distribution) while hemizygous null male conceptuses miscarry. The skin evolves through four classic stages — vesiculobullous, verrucous, swirled hyperpigmentation, and linear hypopigmentation — accompanied by dental, hair, nail, retinal, and central nervous system involvement. The florid eosinophilic inflammation of the first stage is driven by NF-kB-activated eotaxin secreted by the surviving NEMO-competent bystander cells.

Ask OpenScientist

Ask a research question about Incontinentia Pigmenti. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
11
Pathophys.
1
Histopath.
14
Phenotypes
2
Gaps
18
Pathograph
1
Genes
5
Medical Actions
1
References
1
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE DERMATOLOGY
🔗

Mappings

MONDO
MONDO:0010631 incontinentia pigmenti
skos:exactMatch MONDO
MONDO:0010631 (incontinentia pigmenti) is the exact disease concept; its definition names the X-linked dominant, male-lethal IKBKG disorder with Blaschko-linear staged skin lesions.
👪

Inheritance

1
X-linked dominant inheritance HP:0001423
IP is inherited in an X-linked dominant manner and is usually lethal in hemizygous males carrying a null allele. About 65% of affected individuals have a de novo variant. Because male conceptuses with an IKBKG loss-of-function variant miscarry, the expected live-birth ratio for offspring of an affected mother is approximately one-third unaffected females, one-third affected females, and one-third unaffected males. Surviving affected males have a 47,XXY karyotype or somatic mosaicism.
X-linked dominant inheritance
Show evidence (3 references)
PMID:20301645 SUPPORT Other
"male conceptuses with an IKBKG loss-of-function variant miscarry."
Documents the X-linked, male-lethal inheritance of IP.
PMID:20301645 SUPPORT Other
"About 65% of affected individuals have IP as a result of a de novo pathogenic variant."
Quantifies the de novo rate (~65%).
PMID:20301645 SUPPORT Other
"approximately 33% unaffected females, 33% affected females, and 33% unaffected males."
The 33/33/33 live-birth ratio is the direct transmission consequence of male lethality.
?

Discussions and Knowledge Gaps

2
Why is the phenotypic expressivity of IP so highly variable — from skin-limited disease to severe ocular and CNS involvement — when most patients carry the same recurrent exon 4-10 IKBKG deletion, and what determines which organs are affected in a given individual?
KNOWLEDGE GAP OPEN gap_ip_genotype_phenotype
Attached to
pathophysiology#IKBKG (NEMO) Loss of Function pathophysiology#Cerebral Vaso-Occlusive and Neuronal Injury
Because the predominant lesion is a single recurrent null deletion, allele identity alone cannot explain why some individuals have skin-limited disease while others develop sight- or life-threatening ocular and neurologic involvement. The degree and tissue distribution of X-inactivation skewing is a leading candidate modifier, but the genotype-phenotype relationship remains unresolved and limits prognostic counseling.
Show evidence (1 reference)
PMID:36147820 SUPPORT Other
"the clinical genotype-phenotype correlation remains unclear due to its highly variable phenotypic expressivity."
Directly states that the genotype-phenotype correlation is unresolved, defining the gap.
How can IP — a disease of NF-kB LOSS — present with a florid, NF-kB-driven eosinophilic inflammation in its first stage?
INTERPRETATION OPEN interp_ip_bystander_nfkb_paradox
Attached to
pathophysiology#Bystander NF-kB-Competent Eotaxin Secretion and Eosinophil Recruitment pathophysiology#Stage I Vesiculobullous Eruption
The apparent paradox is resolved by mosaicism: the eosinophil-recruiting chemokine eotaxin is NF-kB-activated and is secreted not by the NEMO-null cells but by the surviving NEMO-competent bystander cells that retain the wild-type X as the active allele. The inflammation of IP is therefore produced by the very NF-kB signaling the mutant cells have lost, generated by their normal neighbors — an interpretation important for reading the stage-I histology and for not mistaking IP for a primary inflammatory or infectious dermatosis.
Show evidence (2 references)
PMID:11966763 SUPPORT Model Organism
"are probably produced by the adjacent IKKγ+cells, since NF-κB is not activated in IKKγ"
In the mouse IP model, the NF-kB-activated chemokines are inferred to be produced by the adjacent IKKγ+ (NEMO-competent) bystander cells — the literal basis of the mosaic-bystander resolution of the NF-kB-loss paradox.
PMID:11966763 SUPPORT Human Clinical
"Monoclonal antibody (6H9) specific for human eotaxin strongly labelled the suprabasal epidermis of IP skin, paralleling the upper epidermal accumulation of eosinophils"
Anchors the interpretation in human IP tissue — epidermal eotaxin co-localizes with the epidermal eosinophil accumulation, consistent with the bystander mechanism.
⚙

Pathophysiology

11
IKBKG (NEMO) Loss of Function
Loss-of-function variants in IKBKG abolish or cripple NEMO/IKK-gamma, the regulatory subunit of the IKK complex. The predominant lesion is the recurrent exon 4-10 deletion, a complete null allele; other point and splice variants also occur. Without functional NEMO the IKK complex cannot be activated.
IKBKG hgnc:5961 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves IKBKG (hgnc:5961). hgnc:5961 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Impaired Canonical NF-kB Activation Loss of NEMO prevents assembly/activation of the IKK complex that drives canonical NF-kB signaling.
Show evidence (1 reference)
PMID:36147820 SUPPORT Other
"the Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma (IKBKG) gene located at the Xq28 chromosomal region, which encodes for NEMO/IKKgamma, a regulatory protein involved in the nuclear factor kappa B (NF-κB) signaling pathway."
Identifies IKBKG/NEMO as the regulatory subunit of the NF-kB pathway disrupted in IP.
Impaired Canonical NF-kB Activation
NEMO is required for IKK-mediated activation of canonical NF-kB signaling; its loss prevents NF-kB (RelA/p65) nuclear translocation and transcription of NF-kB target genes, including the anti-apoptotic and inflammatory program. A dysregulated NF-kB pathway is the proximate molecular basis of IP.
canonical NF-kappaB signal transduction GO:0007249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased canonical NF-kappaB signal transduction (GO:0007249). GO:0007249 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Heightened Susceptibility to TNF-Induced Apoptosis Loss of NF-kB-dependent anti-apoptotic gene induction sensitizes NEMO-null cells to TNF-induced death.
Show evidence (1 reference)
PMID:36147820 SUPPORT Other
"IKBKG mutation that results in a loss-of-function or dysregulated NF-κB pathway contributes to the pathophysiology of IP."
Links loss of NEMO to a dysregulated NF-kB pathway as the basis of IP pathophysiology.
Heightened Susceptibility to TNF-Induced Apoptosis
Because NF-kB normally induces anti-apoptotic genes, NEMO-deficient cells (keratinocytes, vascular endothelium, neurons) lose this cytoprotection and become hypersensitive to TNF-induced apoptosis and necrosis — a stimulus that is pro-survival in normal cells becomes lethal. This apoptotic vulnerability is the shared cellular mechanism behind the skin, ocular, and CNS lesions and behind the selective elimination of mutant-X cells.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology. endothelial cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves endothelial cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology.
apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Male Lethality of Null Alleles Apoptotic elimination of mutant-X cells kills hemizygous null male conceptuses while permitting mosaic female survival.
Bystander NF-kB-Competent Eotaxin Secretion and Eosinophil Recruitment Inflammatory signals (TNF, DAMPs) released by dying NEMO-null keratinocytes activate NF-kB in surviving competent neighbors.
Stage I Vesiculobullous Eruption Keratinocyte apoptosis/necrosis initiates the first cutaneous stage.
Retinal Vascular Dysgenesis and Neovascularization Retinal endothelial apoptosis causes peripheral non-perfusion and secondary neovascularization.
Cerebral Vaso-Occlusive and Neuronal Injury Cerebral small-vessel vaso-occlusion and neuronal injury produce the CNS manifestations.
Show evidence (2 references)
PMID:11966763 SUPPORT Human Clinical
"histopathologically by acanthosis, keratinocyte necrosis, epidermal spongiosis and massive epidermal eosinophil infiltration."
Documents keratinocyte necrosis/death in lesional IP skin, reflecting the apoptotic susceptibility of NEMO-null cells.
PMID:16399796 SUPPORT Model Organism
"NEMO deletion completely inhibited NF-kappaB activation and sensitized keratinocytes to tumor necrosis factor (TNF)-induced death but did not affect epidermal development."
Direct in vivo evidence that NEMO loss sensitizes keratinocytes specifically to TNF-induced death (the epidermis-specific NEMO-knockout mouse).
Male Lethality of Null Alleles
Selective apoptotic elimination of cells expressing the mutant IKBKG allele has divergent organism-level outcomes by sex. In affected females the surviving cells preferentially express the wild-type X, producing the mosaic Blaschko-linear distribution and permitting survival. Hemizygous male conceptuses carrying a null allele have no wild-type cells to select for and miscarry; the rare surviving affected males have a 47,XXY karyotype or somatic mosaicism.
Show evidence (3 references)
PMID:20301645 SUPPORT Other
"male conceptuses with an IKBKG loss-of-function variant miscarry."
Documents the male lethality of IKBKG null alleles, the organism-level consequence of selective elimination of mutant-X cells.
PMID:10911992 SUPPORT Model Organism
"Disruption of the X-linked gene encoding NF-kappa B essential modulator (NEMO) produces male embryonic lethality, completely blocks NF-kappa B activation by proinflammatory cytokines"
The NEMO-knockout mouse recapitulates the male embryonic lethality of IP, direct in vivo support for this node.
PMID:10911992 SUPPORT Model Organism
"Surviving mice recover almost completely, presumably through clearing the skin of NEMO-deficient keratinocytes."
Confirms the selective-elimination mechanism — recovery occurs by clearing NEMO-deficient cells, the basis of mosaic survival.
Bystander NF-kB-Competent Eotaxin Secretion and Eosinophil Recruitment
In the mosaic epidermis the surviving NEMO-competent cells (those with the wild-type X active) respond to inflammatory stimuli by activating NF-kB and secreting the eosinophil-selective, NF-kB-activated chemokine eotaxin. This drives the massive epidermal eosinophil infiltration and peripheral eosinophilia that characterize the first (vesiculobullous) stage — the florid inflammation of IP thus arises from the NF-kB that the mutant cells have lost, produced instead by their normal neighbors.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology. eosinophil CL:0000771 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves eosinophil (CL:0000771). CL:0000771 is a cell type from the Cell Ontology.
Downstream
Heightened Susceptibility to TNF-Induced Apoptosis Bystander-secreted TNF feeds back to selectively kill the adjacent NEMO-deficient cells, making the disease self-amplifying.
Stage I Vesiculobullous Eruption Eosinophil recruitment produces the eosinophilic spongiosis of the vesiculobullous stage.
Show evidence (2 references)
PMID:11966763 SUPPORT Human Clinical
"Monoclonal antibody (6H9) specific for human eotaxin strongly labelled the suprabasal epidermis of IP skin, paralleling the upper epidermal accumulation of eosinophils"
Human tissue finding — epidermal eotaxin expression co-localizes with the epidermal eosinophil accumulation in IP skin.
PMID:11966763 SUPPORT In Vitro
"In normal human keratinocytes, proinflammatory cytokines either independently (IL-1alpha) or synergistically (tumour necrosis factor-alpha (TNF-alpha)/ interferon-gamma (IFN-gamma) and TNF-alpha/IL-4) up-regulated eotaxin expression."
Cultured-keratinocyte finding that TNF/IL-1/IFN-gamma induce eotaxin, the mechanism by which NF-kB-competent bystander cells produce it.
Stage I Vesiculobullous Eruption
Keratinocyte apoptosis/necrosis with eosinophilic spongiosis produces the first Blaschko-linear cutaneous stage: an inflammatory vesiculobullous eruption from birth to about age four months.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology.
Downstream
Stage II Verrucous Hyperkeratosis The vesiculobullous lesions evolve into wart-like hyperkeratotic plaques.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Characteristic skin lesions evolve through four stages: I.. Blistering (birth to age ~4 months)."
The vesiculobullous blistering eruption is the first cutaneous stage.
Stage II Verrucous Hyperkeratosis
The second stage is a linear, warty, hyperkeratotic (verrucous) eruption with acanthosis and papillomatosis, evolving over several months.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology.
Downstream
Stage III Dermal Melanophage Pigment Incontinence The verrucous lesions give way to the swirled hyperpigmentation of stage III.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"II.. Wart-like rash (for several months)."
The verrucous (wart-like) plaques constitute the second cutaneous stage.
Stage III Dermal Melanophage Pigment Incontinence
The third stage is the eponymous lesion: melanin is 'incontinent' at the dermal-epidermal junction, dropping from injured basal keratinocytes and melanocytes into dermal macrophages (melanophages), producing swirled, marbled grey-brown hyperpigmentation along Blaschko lines — the finding for which the disease is named.
melanocyte CL:0000148 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves melanocyte (CL:0000148). CL:0000148 is a cell type from the Cell Ontology. macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
Downstream
Stage IV Atrophic Hypopigmentation The hyperpigmentation fades to the atrophic hypopigmented streaks of the final stage.
Show evidence (2 references)
PMID:20301645 SUPPORT Other
"III.. Swirling macular hyperpigmentation (age ~6 months into adulthood)."
The swirled Blaschko-linear hyperpigmentation is the third, eponymous cutaneous stage.
PMID:2003648 SUPPORT Human Clinical
"in hyperpigmented areas we found a reduction of pigment in those parts of the basal layer overlying melanophages located in the upper dermis."
Light/EM study of IP skin documenting the pigment-incontinence mechanism — basal-layer pigment loss overlying dermal melanophages.
Stage IV Atrophic Hypopigmentation
The fourth, adult stage is atrophic linear hypopigmentation — pale, hairless, often atrophic streaks (frequently on the lower legs) along Blaschko lines.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"IV.. Linear hypopigmentation."
Atrophic linear hypopigmentation is the fourth, adult-stage cutaneous manifestation.
Retinal Vascular Dysgenesis and Neovascularization
Apoptosis of retinal vascular endothelium produces peripheral retinal non-perfusion/avascularity; the resulting ischemia drives pathologic neovascularization that predisposes to tractional retinal detachment, the principal cause of vision loss in IP. Foveal/inner-retinal structural abnormalities also occur.
endothelial cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves endothelial cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology.
Show evidence (1 reference)
PMID:26043102 SUPPORT Human Clinical
"Fluorescein angiography showed filling defects in retinal and choroidal circulations and irregularities of the foveal avascular zones."
Documents the retinal vascular non-perfusion/dysgenesis underlying IP retinopathy.
Cerebral Vaso-Occlusive and Neuronal Injury
The CNS manifestations of IP — seizures, intellectual disability, and developmental delay — are believed to arise from cerebral vaso-occlusive events (consistent with the shared endothelial vulnerability of NEMO-null vessels) with secondary neuronal injury. They are among the most prognostically important extracutaneous features, and the underlying mechanism remains incompletely defined.
endothelial cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves endothelial cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology. neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Show evidence (2 references)
PMID:26043102 SUPPORT Human Clinical
"The cause of the CNS anomalies in IP patients is unknown but believed to be from vaso-occlusive events."
Attributes the CNS anomalies of IP to vaso-occlusive events, supporting the vascular mechanism of this node.
PMID:33655605 SUPPORT Human Clinical
"ocular manifestations (28%), neurological abnormalities (28%),"
Quantifies neurological involvement at ~28% of patients, one of the most prognostically important extracutaneous features.
✶

Histopathology

1
Eosinophilic spongiosis with dyskeratotic keratinocytes
The vesiculobullous stage shows acanthosis, keratinocyte necrosis, epidermal spongiosis, and massive intraepidermal eosinophil infiltration (eosinophilic spongiosis). Later stages show dermal melanophages with pigment incontinence (stage III), the feature that names the disease.
Show evidence (2 references)
PMID:11966763 SUPPORT Human Clinical
"histopathologically by acanthosis, keratinocyte necrosis, epidermal spongiosis and massive epidermal eosinophil infiltration."
Documents the eosinophilic spongiosis and keratinocyte necrosis of stage-I IP skin.
PMID:2003648 SUPPORT Human Clinical
"in hyperpigmented areas we found a reduction of pigment in those parts of the basal layer overlying melanophages located in the upper dermis."
Documents the stage-III dermal melanophage pigment incontinence on light/EM microscopy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Incontinentia Pigmenti Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Blood 1
Peripheral eosinophilia Increased total eosinophil count HP:0001880 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased total eosinophil count (HP:0001880). HP:0001880 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11966763 SUPPORT Human Clinical
"Peripheral eosinophilia is usually associated, and may run as high as 70 000 eosinophils per mm3."
Documents the circulating (peripheral blood) eosinophilia that accompanies the stage-I eosinophilic inflammation.
Eye 1
Retinal detachment HP:0000541 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinal detachment (HP:0000541). HP:0000541 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Neovascularization of the retina, present in some individuals, predisposes to retinal detachment."
Tractional retinal detachment is the principal cause of vision loss in IP.
Head and Neck 1
Dental anomalies (hypodontia) FREQUENT HP:0000668 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypodontia (HP:0000668). HP:0000668 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301645 SUPPORT Other
"Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
Hypodontia is a characteristic dental manifestation of IP.
PMID:39623400 SUPPORT Human Clinical
"the involvement of the teeth (58.7%)"
Quantifies dental involvement at 58.7% in the Danish cohort, supporting the FREQUENT band.
Integument 4
Stage I vesiculobullous eruption VERY_FREQUENT Abnormal blistering of the skin HP:0008066 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal blistering of the skin (HP:0008066), qualified as neonatal onset. HP:0008066 is a phenotype from the Human Phenotype Ontology.
Onset: NEONATAL
Show evidence (2 references)
PMID:20301645 SUPPORT Other
"Characteristic skin lesions evolve through four stages: I.. Blistering (birth to age ~4 months)."
The neonatal vesiculobullous (blistering) stage is the first and near-universal cutaneous manifestation.
PMID:39623400 SUPPORT Human Clinical
"blaschkolinear skin lesions reported in 70 (93.3%)"
Quantifies Blaschko-linear skin involvement at 93.3% of the Danish cohort, supporting the VERY_FREQUENT band.
Stage II verrucous lesions Verrucous papule HP:0012500 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Verrucous papule (HP:0012500). HP:0012500 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"II.. Wart-like rash (for several months)."
The verrucous (wart-like) plaques constitute the second cutaneous stage.
Alopecia HP:0001596 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Alopecia (HP:0001596). HP:0001596 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
Alopecia (often vertex, at sites of prior lesions) is a hair manifestation of IP.
Nail dystrophy HP:0008404 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nail dystrophy (HP:0008404). HP:0008404 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
Dystrophic nails are a recognized ectodermal feature of IP.
Nervous System 3
Seizures OCCASIONAL HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301645 SUPPORT Other
"Neurologic findings including seizures, intellectual disability, and developmental delays are occasionally seen."
Seizures are among the occasional but prognostically important CNS manifestations.
PMID:33655605 SUPPORT Human Clinical
"ocular manifestations (28%), neurological abnormalities (28%),"
Quantifies neurological involvement at ~28% of patients, supporting the OCCASIONAL band.
Intellectual disability OCCASIONAL HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Neurologic findings including seizures, intellectual disability, and developmental delays are occasionally seen."
Intellectual disability is an occasional CNS manifestation of IP.
Developmental delay OCCASIONAL Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Neurologic findings including seizures, intellectual disability, and developmental delays are occasionally seen."
Developmental delay is an occasional CNS manifestation of IP.
Other 4
Stage III swirled hyperpigmentation Linear hyperpigmentation HP:0007546 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperpigmentation along Blaschko lines, annotated with Linear hyperpigmentation (HP:0007546). HP:0007546 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"III.. Swirling macular hyperpigmentation (age ~6 months into adulthood)."
The swirled Blaschko-linear hyperpigmentation is the third and most recognizable cutaneous stage.
Stage IV linear hypopigmentation Hypopigmented streaks HP:0007535 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypopigmented streaks (HP:0007535). HP:0007535 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"IV.. Linear hypopigmentation."
Atrophic linear hypopigmentation is the fourth, adult-stage cutaneous manifestation.
Conical teeth Conical tooth HP:0000698 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Conical tooth (HP:0000698). HP:0000698 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
Abnormal (conical) tooth shape is a recognized dental feature of IP.
Peripheral retinal neovascularization OCCASIONAL HP:0030667 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Peripheral retinal neovascularization (HP:0030667). HP:0030667 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301645 SUPPORT Other
"Neovascularization of the retina, present in some individuals, predisposes to retinal detachment."
Retinal neovascularization is the sight-threatening ocular manifestation of IP.
PMID:33655605 SUPPORT Human Clinical
"ocular manifestations (28%), neurological abnormalities (28%),"
Quantifies ocular involvement at ~28% of patients, supporting the OCCASIONAL band.
🧬

Genetic Associations

1
IKBKG
Gene: IKBKG hgnc:5961 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is IKBKG (hgnc:5961). hgnc:5961 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:19603533 SUPPORT Human Clinical
"The major genetic defect in IP is a heterozygous exon4_10 IKBKG deletion (IKBKGdel)"
Establishes the recurrent exon 4-10 IKBKG deletion as the major genetic defect in IP.
💊

Medical Actions

5
Retinal Laser Photocoagulation
Action: laser ablation therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is laser ablation therapy, annotated with Laser Ablation (NCIT:C111241). NCIT:C111241 is a clinical intervention from the NCI Thesaurus. Ontology label: Laser Ablation NCIT:C111241
Ablative laser photocoagulation (and cryotherapy) of peripheral avascular retina and retinal neovascularization is the mainstay sight-preserving intervention, reducing the risk of tractional retinal detachment. Anti-VEGF injection is a second-line adjunct without formal consensus.
Target Phenotypes: Peripheral retinal neovascularization HP:0030667 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Peripheral retinal neovascularization (HP:0030667). HP:0030667 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"cryotherapy and laser photocoagulation of retinal neovascularization to reduce risk of retinal detachment"
Laser photocoagulation/cryotherapy of retinal neovascularization is the standard sight-preserving treatment.
Ophthalmologic Surveillance
Action: eye examinationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is eye examination (NCIT:C38060). NCIT:C38060 is a clinical intervention from the NCI Thesaurus. Ontology label: Eye Examination NCIT:C38060
Because retinopathy can progress rapidly in infancy, frequent eye examinations are recommended — monthly to age four months, then every three months to age one year, every six months to age three years, and annually thereafter.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Eye examination: monthly until age four months, then every three months from age four months to one year, every six months from age one to three years, and annually after age three years."
Specifies the intensive ophthalmologic surveillance schedule that catches sight-threatening retinopathy early.
Supportive Skin and Blister Care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Stage-I blisters and any secondary skin infections are managed with standard wound care and infection-control measures; the eruption is otherwise self-limited as it evolves through the later stages.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"Standard management of blisters and skin infections"
Supportive wound/infection care is the standard approach to the cutaneous disease.
Dental Care and Implants
Action: dental implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dental implantation, annotated with Dental Procedure (NCIT:C38052). NCIT:C38052 is a clinical intervention from the NCI Thesaurus. Ontology label: Dental Procedure NCIT:C38052
Because IP causes hypodontia and abnormal tooth shape, management includes dental care by a pedodontist and dental implants in childhood as needed, with speech/nutrition support when dental abnormalities impair chewing or speech.
Target Phenotypes: Hypodontia HP:0000668 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypodontia (HP:0000668). HP:0000668 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"dental care by a pedodontist; dental implants in childhood as needed"
GeneReviews specifies pedodontic care and childhood dental implants for the dental manifestations.
Neurologic Management
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Seizures, spasticity, and focal deficits are managed by referral to a pediatric neurologist, with brain MRI for functional neurologic abnormalities and developmental/special-education programs as needed.
Target Phenotypes: Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301645 SUPPORT Other
"referral to a pediatric neurologist for management of seizures, spasticity, or focal deficits"
GeneReviews specifies pediatric-neurology referral for the CNS manifestations.
🔬

Diagnosis

1
Clinical Diagnosis and IKBKG Molecular Testing
Diagnosis is established by a characteristic skin lesion (major criterion), supported by identification of a heterozygous IKBKG pathogenic variant in a female (or hemizygous in a male). Molecular testing targets the recurrent exon 4-10 deletion first (long-range PCR / MLPA) followed by sequencing. A truncated IKBKG pseudogene copy (IKBKGP/deltaNEMO) at the same locus complicates sequence analysis and necessitates deletion-specific assays.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:20301645 SUPPORT Other
"The diagnosis of IP is established in a proband with at least one major criterion (characteristic skin lesion). Identification of a heterozygous IKBKG pathogenic variant in a female proband or a hemizygous IKBKG pathogenic variant in a male proband confirms the diagnosis if clinical features are..."
States the clinical major criterion plus IKBKG molecular confirmation.
PMID:19603533 SUPPORT Human Clinical
"its truncated pseudogene copy, IKBKGP/deltaNEMO"
The IKBKG pseudogene at the IP locus complicates molecular diagnosis and requires deletion-specific testing.
📊

Prevalence

1
Denmark
Birth Prevalence 2.37 per 100,000 (1.74–3.25) 1–9 per 100,000
Nationwide Danish population-based birth prevalence, 1995-2023, roughly twice earlier estimates and likely reflecting improved ascertainment; ~94.7% of patients were female.
Show evidence (1 reference)
PMID:39623400 SUPPORT Human Clinical
"We estimated a birth prevalence of 2.37 (95% CI: 1.74-3.25) per 100,000 or 1 in 42,194."
Provides the most robust (nationwide Danish) birth-prevalence estimate for IP.
{ }

Source YAML

click to show 
name: Incontinentia Pigmenti
category: Mendelian
creation_date: "2026-07-30T04:10:00Z"
synonyms:
- Bloch-Sulzberger syndrome
- IP
- IP2
description: >-
  Incontinentia pigmenti (IP) is a rare X-linked dominant, typically
  male-lethal, multisystem ectodermal disorder caused by loss-of-function
  variants in IKBKG (NEMO), the regulatory subunit of the IKK complex required
  for canonical NF-kB activation. Loss of NEMO removes the NF-kB-dependent
  cytoprotective program, so mutant cells become hypersensitive to
  TNF-induced apoptosis; the selective elimination of cells expressing the
  mutant X produces extremely skewed X-inactivation (allowing female survival
  and the mosaic Blaschko-linear distribution) while hemizygous null male
  conceptuses miscarry. The skin evolves through four classic stages —
  vesiculobullous, verrucous, swirled hyperpigmentation, and linear
  hypopigmentation — accompanied by dental, hair, nail, retinal, and central
  nervous system involvement. The florid eosinophilic inflammation of the first
  stage is driven by NF-kB-activated eotaxin secreted by the surviving
  NEMO-competent bystander cells.
disease_term:
  preferred_term: incontinentia pigmenti
  term:
    id: MONDO:0010631
    label: incontinentia pigmenti
parents:
- Ectodermal Dysplasia
- X-linked Genodermatosis
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010631
      label: incontinentia pigmenti
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0010631 (incontinentia pigmenti) is the exact disease concept; its
      definition names the X-linked dominant, male-lethal IKBKG disorder with
      Blaschko-linear staged skin lesions.
references:
- reference: PMID:20301645
  title: "Incontinentia Pigmenti."
  tags:
  - GeneReviews
inheritance:
- name: X-linked dominant inheritance
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
  description: >-
    IP is inherited in an X-linked dominant manner and is usually lethal in
    hemizygous males carrying a null allele. About 65% of affected individuals
    have a de novo variant. Because male conceptuses with an IKBKG
    loss-of-function variant miscarry, the expected live-birth ratio for
    offspring of an affected mother is approximately one-third unaffected
    females, one-third affected females, and one-third unaffected males.
    Surviving affected males have a 47,XXY karyotype or somatic mosaicism.
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "male conceptuses with an IKBKG loss-of-function variant miscarry."
    explanation: Documents the X-linked, male-lethal inheritance of IP.
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "About 65% of affected individuals have IP as a result of a de novo pathogenic variant."
    explanation: Quantifies the de novo rate (~65%).
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "approximately 33% unaffected females, 33% affected females, and 33% unaffected males."
    explanation: The 33/33/33 live-birth ratio is the direct transmission consequence of male lethality.
genetic:
- name: IKBKG
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: IKBKG
    term:
      id: hgnc:5961
      label: IKBKG
  notes: >-
    IP is caused by loss-of-function variants in IKBKG (NEMO). The major
    genetic defect (~65-80% of unrelated probands) is a recurrent heterozygous
    deletion of exons 4-10 (IKBKGdel), a complete-loss-of-function allele
    generated by recombination at the structurally unstable Xq28 locus; the
    remainder carry small indels, nonsense, or splice-site variants. The exon
    4-10 deletion recurs independently in unrelated families (a recurrent
    rearrangement, not a single ancestral founder allele). IKBKG is allelic with
    a distinct disorder: hypomorphic (partial-function) IKBKG variants in
    hemizygous males cause ectodermal dysplasia with immunodeficiency (EDA-ID; see
    the IKBKG_Ectodermal_Dysplasia_with_Immunodeficiency entry), whereas the
    null alleles here cause male-lethal incontinentia pigmenti in heterozygous
    females.
  evidence:
  - reference: PMID:19603533
    reference_title: "Microdeletion/duplication at the Xq28 IP locus causes a de novo IKBKG/NEMO/IKKgamma exon4_10 deletion in families with Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major genetic defect in IP is a heterozygous exon4_10 IKBKG deletion (IKBKGdel)"
    explanation: Establishes the recurrent exon 4-10 IKBKG deletion as the major genetic defect in IP.
pathophysiology:
- name: IKBKG (NEMO) Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Loss-of-function variants in IKBKG abolish or cripple NEMO/IKK-gamma, the
    regulatory subunit of the IKK complex. The predominant lesion is the
    recurrent exon 4-10 deletion, a complete null allele; other point and
    splice variants also occur. Without functional NEMO the IKK complex cannot
    be activated.
  genes:
  - preferred_term: IKBKG
    term:
      id: hgnc:5961
      label: IKBKG
  evidence:
  - reference: PMID:36147820
    reference_title: "Uncovering incontinentia pigmenti: From DNA sequence to pathophysiology."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma (IKBKG) gene located at the Xq28 chromosomal region, which encodes for NEMO/IKKgamma, a regulatory protein involved in the nuclear factor kappa B (NF-κB) signaling pathway."
    explanation: Identifies IKBKG/NEMO as the regulatory subunit of the NF-kB pathway disrupted in IP.
  downstream:
  - target: Impaired Canonical NF-kB Activation
    description: Loss of NEMO prevents assembly/activation of the IKK complex that drives canonical NF-kB signaling.
    causal_link_type: DIRECT
- name: Impaired Canonical NF-kB Activation
  biological_scale: MOLECULAR
  description: >-
    NEMO is required for IKK-mediated activation of canonical NF-kB signaling;
    its loss prevents NF-kB (RelA/p65) nuclear translocation and transcription
    of NF-kB target genes, including the anti-apoptotic and inflammatory
    program. A dysregulated NF-kB pathway is the proximate molecular basis of
    IP.
  biological_processes:
  - preferred_term: canonical NF-kappaB signal transduction
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
    modifier: DECREASED
  evidence:
  - reference: PMID:36147820
    reference_title: "Uncovering incontinentia pigmenti: From DNA sequence to pathophysiology."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IKBKG mutation that results in a loss-of-function or dysregulated NF-κB pathway contributes to the pathophysiology of IP."
    explanation: Links loss of NEMO to a dysregulated NF-kB pathway as the basis of IP pathophysiology.
  downstream:
  - target: Heightened Susceptibility to TNF-Induced Apoptosis
    description: Loss of NF-kB-dependent anti-apoptotic gene induction sensitizes NEMO-null cells to TNF-induced death.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36147820
      reference_title: "Uncovering incontinentia pigmenti: From DNA sequence to pathophysiology."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "NF-κB plays a prominent role in the modulation of cellular proliferation, apoptosis, and inflammation."
      explanation: NF-kB controls the anti-apoptotic program whose loss sensitizes cells to apoptosis.
- name: Heightened Susceptibility to TNF-Induced Apoptosis
  biological_scale: CELLULAR
  description: >-
    Because NF-kB normally induces anti-apoptotic genes, NEMO-deficient cells
    (keratinocytes, vascular endothelium, neurons) lose this cytoprotection and
    become hypersensitive to TNF-induced apoptosis and necrosis — a stimulus
    that is pro-survival in normal cells becomes lethal. This apoptotic
    vulnerability is the shared cellular mechanism behind the skin, ocular, and
    CNS lesions and behind the selective elimination of mutant-X cells.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:11966763
    reference_title: "Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "histopathologically by acanthosis, keratinocyte necrosis, epidermal spongiosis and massive epidermal eosinophil infiltration."
    explanation: Documents keratinocyte necrosis/death in lesional IP skin, reflecting the apoptotic susceptibility of NEMO-null cells.
  - reference: PMID:16399796
    reference_title: "Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "NEMO deletion completely inhibited NF-kappaB activation and sensitized keratinocytes to tumor necrosis factor (TNF)-induced death but did not affect epidermal development."
    explanation: Direct in vivo evidence that NEMO loss sensitizes keratinocytes specifically to TNF-induced death (the epidermis-specific NEMO-knockout mouse).
  downstream:
  - target: Male Lethality of Null Alleles
    description: Apoptotic elimination of mutant-X cells kills hemizygous null male conceptuses while permitting mosaic female survival.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Bystander NF-kB-Competent Eotaxin Secretion and Eosinophil Recruitment
    description: Inflammatory signals (TNF, DAMPs) released by dying NEMO-null keratinocytes activate NF-kB in surviving competent neighbors.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Stage I Vesiculobullous Eruption
    description: Keratinocyte apoptosis/necrosis initiates the first cutaneous stage.
    causal_link_type: DIRECT
  - target: Retinal Vascular Dysgenesis and Neovascularization
    description: Retinal endothelial apoptosis causes peripheral non-perfusion and secondary neovascularization.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Cerebral Vaso-Occlusive and Neuronal Injury
    description: Cerebral small-vessel vaso-occlusion and neuronal injury produce the CNS manifestations.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Male Lethality of Null Alleles
  biological_scale: ORGANISM
  description: >-
    Selective apoptotic elimination of cells expressing the mutant IKBKG allele
    has divergent organism-level outcomes by sex. In affected females the
    surviving cells preferentially express the wild-type X, producing the mosaic
    Blaschko-linear distribution and permitting survival. Hemizygous male
    conceptuses carrying a null allele have no wild-type cells to select for and
    miscarry; the rare surviving affected males have a 47,XXY karyotype or
    somatic mosaicism.
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "male conceptuses with an IKBKG loss-of-function variant miscarry."
    explanation: Documents the male lethality of IKBKG null alleles, the organism-level consequence of selective elimination of mutant-X cells.
  - reference: PMID:10911992
    reference_title: "NEMO/IKK gamma-deficient mice model incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Disruption of the X-linked gene encoding NF-kappa B essential modulator (NEMO) produces male embryonic lethality, completely blocks NF-kappa B activation by proinflammatory cytokines"
    explanation: The NEMO-knockout mouse recapitulates the male embryonic lethality of IP, direct in vivo support for this node.
  - reference: PMID:10911992
    reference_title: "NEMO/IKK gamma-deficient mice model incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Surviving mice recover almost completely, presumably through clearing the skin of NEMO-deficient keratinocytes."
    explanation: Confirms the selective-elimination mechanism — recovery occurs by clearing NEMO-deficient cells, the basis of mosaic survival.
- name: Bystander NF-kB-Competent Eotaxin Secretion and Eosinophil Recruitment
  biological_scale: CELLULAR
  description: >-
    In the mosaic epidermis the surviving NEMO-competent cells (those with the
    wild-type X active) respond to inflammatory stimuli by activating NF-kB and
    secreting the eosinophil-selective, NF-kB-activated chemokine eotaxin. This
    drives the massive epidermal eosinophil infiltration and peripheral
    eosinophilia that characterize the first (vesiculobullous) stage — the
    florid inflammation of IP thus arises from the NF-kB that the mutant cells
    have lost, produced instead by their normal neighbors.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  - preferred_term: eosinophil
    term:
      id: CL:0000771
      label: eosinophil
  evidence:
  - reference: PMID:11966763
    reference_title: "Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Monoclonal antibody (6H9) specific for human eotaxin strongly labelled the suprabasal epidermis of IP skin, paralleling the upper epidermal accumulation of eosinophils"
    explanation: Human tissue finding — epidermal eotaxin expression co-localizes with the epidermal eosinophil accumulation in IP skin.
  - reference: PMID:11966763
    reference_title: "Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In normal human keratinocytes, proinflammatory cytokines either independently (IL-1alpha) or synergistically (tumour necrosis factor-alpha (TNF-alpha)/ interferon-gamma (IFN-gamma) and TNF-alpha/IL-4) up-regulated eotaxin expression."
    explanation: Cultured-keratinocyte finding that TNF/IL-1/IFN-gamma induce eotaxin, the mechanism by which NF-kB-competent bystander cells produce it.
  downstream:
  - target: Heightened Susceptibility to TNF-Induced Apoptosis
    description: Bystander-secreted TNF feeds back to selectively kill the adjacent NEMO-deficient cells, making the disease self-amplifying.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Stage I Vesiculobullous Eruption
    description: Eosinophil recruitment produces the eosinophilic spongiosis of the vesiculobullous stage.
    causal_link_type: DIRECT
- name: Stage I Vesiculobullous Eruption
  biological_scale: TISSUE
  description: >-
    Keratinocyte apoptosis/necrosis with eosinophilic spongiosis produces the
    first Blaschko-linear cutaneous stage: an inflammatory vesiculobullous
    eruption from birth to about age four months.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Characteristic skin lesions evolve through four stages: I.. Blistering (birth to age ~4 months)."
    explanation: The vesiculobullous blistering eruption is the first cutaneous stage.
  downstream:
  - target: Stage II Verrucous Hyperkeratosis
    description: The vesiculobullous lesions evolve into wart-like hyperkeratotic plaques.
    causal_link_type: DIRECT
- name: Stage II Verrucous Hyperkeratosis
  biological_scale: TISSUE
  description: >-
    The second stage is a linear, warty, hyperkeratotic (verrucous) eruption
    with acanthosis and papillomatosis, evolving over several months.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "II.. Wart-like rash (for several months)."
    explanation: The verrucous (wart-like) plaques constitute the second cutaneous stage.
  downstream:
  - target: Stage III Dermal Melanophage Pigment Incontinence
    description: The verrucous lesions give way to the swirled hyperpigmentation of stage III.
    causal_link_type: DIRECT
- name: Stage III Dermal Melanophage Pigment Incontinence
  biological_scale: TISSUE
  description: >-
    The third stage is the eponymous lesion: melanin is 'incontinent' at the
    dermal-epidermal junction, dropping from injured basal keratinocytes and
    melanocytes into dermal macrophages (melanophages), producing swirled,
    marbled grey-brown hyperpigmentation along Blaschko lines — the finding for
    which the disease is named.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "III.. Swirling macular hyperpigmentation (age ~6 months into adulthood)."
    explanation: The swirled Blaschko-linear hyperpigmentation is the third, eponymous cutaneous stage.
  - reference: PMID:2003648
    reference_title: "Hypo- and hyperpigmented areas in incontinentia pigmenti. Light and electron microscopic studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in hyperpigmented areas we found a reduction of pigment in those parts of the basal layer overlying melanophages located in the upper dermis."
    explanation: Light/EM study of IP skin documenting the pigment-incontinence mechanism — basal-layer pigment loss overlying dermal melanophages.
  downstream:
  - target: Stage IV Atrophic Hypopigmentation
    description: The hyperpigmentation fades to the atrophic hypopigmented streaks of the final stage.
    causal_link_type: DIRECT
- name: Stage IV Atrophic Hypopigmentation
  biological_scale: TISSUE
  description: >-
    The fourth, adult stage is atrophic linear hypopigmentation — pale,
    hairless, often atrophic streaks (frequently on the lower legs) along
    Blaschko lines.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IV.. Linear hypopigmentation."
    explanation: Atrophic linear hypopigmentation is the fourth, adult-stage cutaneous manifestation.
- name: Retinal Vascular Dysgenesis and Neovascularization
  biological_scale: TISSUE
  description: >-
    Apoptosis of retinal vascular endothelium produces peripheral retinal
    non-perfusion/avascularity; the resulting ischemia drives pathologic
    neovascularization that predisposes to tractional retinal detachment, the
    principal cause of vision loss in IP. Foveal/inner-retinal structural
    abnormalities also occur.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  evidence:
  - reference: PMID:26043102
    reference_title: "Structural Abnormalities of the Inner Macula in Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fluorescein angiography showed filling defects in retinal and choroidal circulations and irregularities of the foveal avascular zones."
    explanation: Documents the retinal vascular non-perfusion/dysgenesis underlying IP retinopathy.
- name: Cerebral Vaso-Occlusive and Neuronal Injury
  biological_scale: TISSUE
  description: >-
    The CNS manifestations of IP — seizures, intellectual disability, and
    developmental delay — are believed to arise from cerebral vaso-occlusive
    events (consistent with the shared endothelial vulnerability of NEMO-null
    vessels) with secondary neuronal injury. They are among the most
    prognostically important extracutaneous features, and the underlying
    mechanism remains incompletely defined.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:26043102
    reference_title: "Structural Abnormalities of the Inner Macula in Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cause of the CNS anomalies in IP patients is unknown but believed to be from vaso-occlusive events."
    explanation: Attributes the CNS anomalies of IP to vaso-occlusive events, supporting the vascular mechanism of this node.
  - reference: PMID:33655605
    reference_title: "Importance of extracutaneous organ involvement in determining the clinical severity and prognosis of incontinentia pigmenti caused by mutations in the IKBKG gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ocular manifestations (28%), neurological abnormalities (28%),"
    explanation: Quantifies neurological involvement at ~28% of patients, one of the most prognostically important extracutaneous features.
phenotypes:
- category: Dermatological
  name: Stage I vesiculobullous eruption
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Abnormal blistering of the skin
    term:
      id: HP:0008066
      label: Abnormal blistering of the skin
    onset:
      onset_category: NEONATAL
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Characteristic skin lesions evolve through four stages: I.. Blistering (birth to age ~4 months)."
    explanation: The neonatal vesiculobullous (blistering) stage is the first and near-universal cutaneous manifestation.
  - reference: PMID:39623400
    reference_title: "Prevalence and clinical characteristics of incontinentia pigmenti: a nationwide population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "blaschkolinear skin lesions reported in 70 (93.3%)"
    explanation: Quantifies Blaschko-linear skin involvement at 93.3% of the Danish cohort, supporting the VERY_FREQUENT band.
- category: Dermatological
  name: Stage II verrucous lesions
  phenotype_term:
    preferred_term: Verrucous papule
    term:
      id: HP:0012500
      label: Verrucous papule
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "II.. Wart-like rash (for several months)."
    explanation: The verrucous (wart-like) plaques constitute the second cutaneous stage.
- category: Dermatological
  name: Stage III swirled hyperpigmentation
  phenotype_term:
    preferred_term: Hyperpigmentation along Blaschko lines
    term:
      id: HP:0007546
      label: Linear hyperpigmentation
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "III.. Swirling macular hyperpigmentation (age ~6 months into adulthood)."
    explanation: The swirled Blaschko-linear hyperpigmentation is the third and most recognizable cutaneous stage.
- category: Dermatological
  name: Stage IV linear hypopigmentation
  phenotype_term:
    preferred_term: Hypopigmented streaks
    term:
      id: HP:0007535
      label: Hypopigmented streaks
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IV.. Linear hypopigmentation."
    explanation: Atrophic linear hypopigmentation is the fourth, adult-stage cutaneous manifestation.
- category: Dental
  name: Dental anomalies (hypodontia)
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypodontia
    term:
      id: HP:0000668
      label: Hypodontia
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
    explanation: Hypodontia is a characteristic dental manifestation of IP.
  - reference: PMID:39623400
    reference_title: "Prevalence and clinical characteristics of incontinentia pigmenti: a nationwide population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the involvement of the teeth (58.7%)"
    explanation: Quantifies dental involvement at 58.7% in the Danish cohort, supporting the FREQUENT band.
- category: Dental
  name: Conical teeth
  phenotype_term:
    preferred_term: Conical tooth
    term:
      id: HP:0000698
      label: Conical tooth
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
    explanation: Abnormal (conical) tooth shape is a recognized dental feature of IP.
- category: Dermatological
  name: Alopecia
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
    explanation: Alopecia (often vertex, at sites of prior lesions) is a hair manifestation of IP.
- category: Dermatological
  name: Nail dystrophy
  phenotype_term:
    preferred_term: Nail dystrophy
    term:
      id: HP:0008404
      label: Nail dystrophy
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Alopecia, hypodontia, abnormal tooth shape, and dystrophic nails are observed."
    explanation: Dystrophic nails are a recognized ectodermal feature of IP.
- category: Ophthalmological
  name: Peripheral retinal neovascularization
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Peripheral retinal neovascularization
    term:
      id: HP:0030667
      label: Peripheral retinal neovascularization
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neovascularization of the retina, present in some individuals, predisposes to retinal detachment."
    explanation: Retinal neovascularization is the sight-threatening ocular manifestation of IP.
  - reference: PMID:33655605
    reference_title: "Importance of extracutaneous organ involvement in determining the clinical severity and prognosis of incontinentia pigmenti caused by mutations in the IKBKG gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ocular manifestations (28%), neurological abnormalities (28%),"
    explanation: Quantifies ocular involvement at ~28% of patients, supporting the OCCASIONAL band.
- category: Ophthalmological
  name: Retinal detachment
  phenotype_term:
    preferred_term: Retinal detachment
    term:
      id: HP:0000541
      label: Retinal detachment
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neovascularization of the retina, present in some individuals, predisposes to retinal detachment."
    explanation: Tractional retinal detachment is the principal cause of vision loss in IP.
- category: Neurological
  name: Seizures
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurologic findings including seizures, intellectual disability, and developmental delays are occasionally seen."
    explanation: Seizures are among the occasional but prognostically important CNS manifestations.
  - reference: PMID:33655605
    reference_title: "Importance of extracutaneous organ involvement in determining the clinical severity and prognosis of incontinentia pigmenti caused by mutations in the IKBKG gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ocular manifestations (28%), neurological abnormalities (28%),"
    explanation: Quantifies neurological involvement at ~28% of patients, supporting the OCCASIONAL band.
- category: Neurological
  name: Intellectual disability
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurologic findings including seizures, intellectual disability, and developmental delays are occasionally seen."
    explanation: Intellectual disability is an occasional CNS manifestation of IP.
- category: Neurological
  name: Developmental delay
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurologic findings including seizures, intellectual disability, and developmental delays are occasionally seen."
    explanation: Developmental delay is an occasional CNS manifestation of IP.
- category: Hematological
  name: Peripheral eosinophilia
  phenotype_term:
    preferred_term: Increased total eosinophil count
    term:
      id: HP:0001880
      label: Increased total eosinophil count
  evidence:
  - reference: PMID:11966763
    reference_title: "Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Peripheral eosinophilia is usually associated, and may run as high as 70 000 eosinophils per mm3."
    explanation: Documents the circulating (peripheral blood) eosinophilia that accompanies the stage-I eosinophilic inflammation.
histopathology:
- name: Eosinophilic spongiosis with dyskeratotic keratinocytes
  description: >-
    The vesiculobullous stage shows acanthosis, keratinocyte necrosis,
    epidermal spongiosis, and massive intraepidermal eosinophil infiltration
    (eosinophilic spongiosis). Later stages show dermal melanophages with pigment
    incontinence (stage III), the feature that names the disease.
  evidence:
  - reference: PMID:11966763
    reference_title: "Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "histopathologically by acanthosis, keratinocyte necrosis, epidermal spongiosis and massive epidermal eosinophil infiltration."
    explanation: Documents the eosinophilic spongiosis and keratinocyte necrosis of stage-I IP skin.
  - reference: PMID:2003648
    reference_title: "Hypo- and hyperpigmented areas in incontinentia pigmenti. Light and electron microscopic studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in hyperpigmented areas we found a reduction of pigment in those parts of the basal layer overlying melanophages located in the upper dermis."
    explanation: Documents the stage-III dermal melanophage pigment incontinence on light/EM microscopy.
diagnosis:
- name: Clinical Diagnosis and IKBKG Molecular Testing
  description: >-
    Diagnosis is established by a characteristic skin lesion (major criterion),
    supported by identification of a heterozygous IKBKG pathogenic variant in a
    female (or hemizygous in a male). Molecular testing targets the recurrent
    exon 4-10 deletion first (long-range PCR / MLPA) followed by sequencing. A
    truncated IKBKG pseudogene copy (IKBKGP/deltaNEMO) at the same locus
    complicates sequence analysis and necessitates deletion-specific assays.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of IP is established in a proband with at least one major criterion (characteristic skin lesion). Identification of a heterozygous IKBKG pathogenic variant in a female proband or a hemizygous IKBKG pathogenic variant in a male proband confirms the diagnosis if clinical features are inconclusive."
    explanation: States the clinical major criterion plus IKBKG molecular confirmation.
  - reference: PMID:19603533
    reference_title: "Microdeletion/duplication at the Xq28 IP locus causes a de novo IKBKG/NEMO/IKKgamma exon4_10 deletion in families with Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "its truncated pseudogene copy, IKBKGP/deltaNEMO"
    explanation: The IKBKG pseudogene at the IP locus complicates molecular diagnosis and requires deletion-specific testing.
treatments:
- name: Retinal Laser Photocoagulation
  description: >-
    Ablative laser photocoagulation (and cryotherapy) of peripheral avascular
    retina and retinal neovascularization is the mainstay sight-preserving
    intervention, reducing the risk of tractional retinal detachment. Anti-VEGF
    injection is a second-line adjunct without formal consensus.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: laser ablation therapy
    term:
      id: NCIT:C111241
      label: Laser Ablation
  target_phenotypes:
  - preferred_term: Peripheral retinal neovascularization
    term:
      id: HP:0030667
      label: Peripheral retinal neovascularization
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "cryotherapy and laser photocoagulation of retinal neovascularization to reduce risk of retinal detachment"
    explanation: Laser photocoagulation/cryotherapy of retinal neovascularization is the standard sight-preserving treatment.
- name: Ophthalmologic Surveillance
  description: >-
    Because retinopathy can progress rapidly in infancy, frequent eye
    examinations are recommended — monthly to age four months, then every three
    months to age one year, every six months to age three years, and annually
    thereafter.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: eye examination
    term:
      id: NCIT:C38060
      label: Eye Examination
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Eye examination: monthly until age four months, then every three months from age four months to one year, every six months from age one to three years, and annually after age three years."
    explanation: Specifies the intensive ophthalmologic surveillance schedule that catches sight-threatening retinopathy early.
- name: Supportive Skin and Blister Care
  description: >-
    Stage-I blisters and any secondary skin infections are managed with standard
    wound care and infection-control measures; the eruption is otherwise
    self-limited as it evolves through the later stages.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Standard management of blisters and skin infections"
    explanation: Supportive wound/infection care is the standard approach to the cutaneous disease.
- name: Dental Care and Implants
  description: >-
    Because IP causes hypodontia and abnormal tooth shape, management includes
    dental care by a pedodontist and dental implants in childhood as needed,
    with speech/nutrition support when dental abnormalities impair chewing or
    speech.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: dental implantation
    term:
      id: NCIT:C38052
      label: Dental Procedure
  target_phenotypes:
  - preferred_term: Hypodontia
    term:
      id: HP:0000668
      label: Hypodontia
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "dental care by a pedodontist; dental implants in childhood as needed"
    explanation: GeneReviews specifies pedodontic care and childhood dental implants for the dental manifestations.
- name: Neurologic Management
  description: >-
    Seizures, spasticity, and focal deficits are managed by referral to a
    pediatric neurologist, with brain MRI for functional neurologic
    abnormalities and developmental/special-education programs as needed.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20301645
    reference_title: "Incontinentia Pigmenti."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "referral to a pediatric neurologist for management of seizures, spasticity, or focal deficits"
    explanation: GeneReviews specifies pediatric-neurology referral for the CNS manifestations.
prevalence:
- population: Denmark
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 2.37
  rate_low: 1.74
  rate_high: 3.25
  notes: >-
    Nationwide Danish population-based birth prevalence, 1995-2023, roughly
    twice earlier estimates and likely reflecting improved ascertainment;
    ~94.7% of patients were female.
  evidence:
  - reference: PMID:39623400
    reference_title: "Prevalence and clinical characteristics of incontinentia pigmenti: a nationwide population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We estimated a birth prevalence of 2.37 (95% CI: 1.74-3.25) per 100,000 or 1 in 42,194."
    explanation: Provides the most robust (nationwide Danish) birth-prevalence estimate for IP.
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:36147820
      reference_title: "Uncovering incontinentia pigmenti: From DNA sequence to pathophysiology."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Incontinentia pigmenti (IP) is an X-linked dominant genodermatosis."
      explanation: Characterizes IP as an X-linked (Mendelian) genodermatosis.
  - classification_value: DERMATOLOGY
    evidence:
    - reference: PMID:20301645
      reference_title: "Incontinentia Pigmenti."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Incontinentia pigmenti (IP) is a disorder that affects the skin, hair, teeth, nails, eyes, and central nervous system"
      explanation: IP is primarily a genodermatosis with prominent skin involvement.
discussions:
- discussion_id: gap_ip_genotype_phenotype
  prompt: >-
    Why is the phenotypic expressivity of IP so highly variable — from
    skin-limited disease to severe ocular and CNS involvement — when most
    patients carry the same recurrent exon 4-10 IKBKG deletion, and what
    determines which organs are affected in a given individual?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#IKBKG (NEMO) Loss of Function
  - pathophysiology#Cerebral Vaso-Occlusive and Neuronal Injury
  rationale: >-
    Because the predominant lesion is a single recurrent null deletion, allele
    identity alone cannot explain why some individuals have skin-limited disease
    while others develop sight- or life-threatening ocular and neurologic
    involvement. The degree and tissue distribution of X-inactivation skewing is
    a leading candidate modifier, but the genotype-phenotype relationship
    remains unresolved and limits prognostic counseling.
  evidence:
  - reference: PMID:36147820
    reference_title: "Uncovering incontinentia pigmenti: From DNA sequence to pathophysiology."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the clinical genotype-phenotype correlation remains unclear due to its highly variable phenotypic expressivity."
    explanation: Directly states that the genotype-phenotype correlation is unresolved, defining the gap.
- discussion_id: interp_ip_bystander_nfkb_paradox
  prompt: >-
    How can IP — a disease of NF-kB LOSS — present with a florid, NF-kB-driven
    eosinophilic inflammation in its first stage?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - pathophysiology#Bystander NF-kB-Competent Eotaxin Secretion and Eosinophil Recruitment
  - pathophysiology#Stage I Vesiculobullous Eruption
  rationale: >-
    The apparent paradox is resolved by mosaicism: the eosinophil-recruiting
    chemokine eotaxin is NF-kB-activated and is secreted not by the NEMO-null
    cells but by the surviving NEMO-competent bystander cells that retain the
    wild-type X as the active allele. The inflammation of IP is therefore
    produced by the very NF-kB signaling the mutant cells have lost, generated
    by their normal neighbors — an interpretation important for reading the
    stage-I histology and for not mistaking IP for a primary inflammatory or
    infectious dermatosis.
  evidence:
  - reference: PMID:11966763
    reference_title: "Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "are probably produced by the adjacent IKKγ+cells, since NF-κB is not activated in IKKγ"
    explanation: In the mouse IP model, the NF-kB-activated chemokines are inferred to be produced by the adjacent IKKγ+ (NEMO-competent) bystander cells — the literal basis of the mosaic-bystander resolution of the NF-kB-loss paradox.
  - reference: PMID:11966763
    reference_title: "Expression of eotaxin, an eosinophil-selective chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Monoclonal antibody (6H9) specific for human eotaxin strongly labelled the suprabasal epidermis of IP skin, paralleling the upper epidermal accumulation of eosinophils"
    explanation: Anchors the interpretation in human IP tissue — epidermal eotaxin co-localizes with the epidermal eosinophil accumulation, consistent with the bystander mechanism.
datasets: []
📚

References & Deep Research

References

1
PMID:20301645
Incontinentia Pigmenti.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
Incontinentia Pigmenti (IP) — Comprehensive Disease Characteristics Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 62 citations 2026-07-30T04:04:17.338597

Incontinentia Pigmenti (IP) — Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview: Incontinentia pigmenti (IP; also called Bloch-Sulzberger syndrome) is a rare, multisystem, X-linked dominant genodermatosis caused by loss-of-function variants in IKBKG (formerly NEMO), the regulatory subunit of the IκB kinase (IKK) complex required for canonical NF-κB activation. It is characterized by four sequential (though often overlapping and irregularly timed) stages of skin lesions following the lines of Blaschko, together with variable involvement of teeth, hair, nails, eyes, and the central nervous system (CNS). It is X-linked dominant and male-lethal in utero for the common null allele — the disease is seen almost exclusively in females, who survive because of functional X-chromosome mosaicism (lyonization) (StatPearls, NBK578194; GeneReviews, NBK1472).

Key identifiers: - OMIM: #308300 (Incontinentia Pigmenti) (OMIM #308300) - Related allelic disorder: OMIM #300291 — Ectodermal Dysplasia and Immunodeficiency 1 (EDA-ID1), from hypomorphic IKBKG alleles in males - Orphanet: ORPHA:464 (Orphanet: Incontinentia pigmenti) - MONDO: MONDO:0010631 - ICD-10: Q82.3; ICD-11: LD27 / EA90 (skin pigmentation disorders, genetic) - MeSH: D007184 (Incontinentia Pigmenti) - Gene: IKBKG/NEMO, HGNC:5961, Xq28

Synonyms: Bloch-Sulzberger syndrome; Bloch-Siemens syndrome; melanoblastosis cutis linearis; pigmented dermatosis, Siemens-Bloch type; NEMO deficiency syndrome (for the allelic immunodeficiency phenotype).

Evidence basis: Most literature is aggregated disease-level data from case series, national/regional registries, and systematic reviews (rather than large-scale EHR studies), reflecting the disease's rarity. The most recent, methodologically strongest source is a Danish nationwide population-based cohort (n=75, validated via the Danish National Patient Registry) that is more representative than earlier tertiary-referral case series (Herlin et al. 2024, PMID:39623400; PMC11613904).

2. Etiology

Disease causal factor — genetic, monogenic: IP is caused by heterozygous (in females) loss-of-function pathogenic variants in IKBKG/NEMO on Xq28. It is a purely genetic/genomic disorder; there is no known environmental, infectious, or lifestyle contribution to the primary lesion. The mutation typically arises de novo (~65% of cases) but can be inherited from an unaffected or mildly affected mosaic mother (~35%) (GeneReviews NBK1472).

Genetic risk factor — the recurrent IKBKGdel (exon 4–10 deletion): The overwhelming majority (≈65–80% of unrelated probands) carry an identical 11.7-kb deletion removing exons 4–10 of IKBKG, which abolishes protein function entirely. This deletion is generated by non-allelic homologous recombination (NAHR) between two 870-bp direct repeats termed MER67B, one in intron 3 and one downstream of exon 10 — a genomic architecture that makes this a true recurrent rearrangement rather than an independent mutational event in each family (International IP Consortium / Fusco et al., PMID:19603533; Frontiers Pediatr. 2022, PMC9485571). The remainder of cases carry small deletions/insertions, nonsense, splice-site, or (rarely) missense variants scattered across the gene; complete gene deletions (removing neighboring genes) also occur via Xq28 microdeletion/microduplication mechanisms at this same locus.

Environmental risk factors: None established — IP is not associated with parental age, toxin exposure, infection, or in utero exposures. Because the mutation is X-linked and typically lethal to hemizygous male conceptuses, sex (female) is itself the dominant "risk factor" for a liveborn, clinically recognized case.

Protective / modifying factors: - Skewed X-chromosome inactivation (XCI): In affected females, cells expressing the mutant allele undergo NEMO-dependent apoptotic elimination (loss of NF-κB-mediated anti-apoptotic signaling upon TNF exposure), producing extremely skewed XCI in blood and skin toward the wild-type allele by birth. This skewing is itself the mechanism by which affected females survive and is a diagnostic/counseling tool (X-inactivation studies in unaffected relatives) (GeneReviews NBK1472; PMC7767561). - Mechanisms permitting male survival (rare): (1) somatic post-zygotic mosaicism for the deletion (mixture of mutant and wild-type cells, analogous to female lyonization); (2) 47,XXY karyotype (Klinefelter syndrome), which supplies a second X allele and allows skewed inactivation as in females; (3) hypomorphic (partial-function) missense/point variants rather than the null exon 4–10 deletion, which are compatible with hemizygous male survival but typically produce a distinct, more immunodeficiency-predominant phenotype (EDA-ID) rather than classic IP (Bruynseels et al./AJHG, PMID:11673821; Cell.com Survival of Male Patients). - Gene-environment interaction: Not a feature of this disease — pathogenesis is cell-autonomous (keratinocyte genotype × TNF-family cytokine exposure), not an external environmental modifier per se; see Mechanism section for the TNF-triggered apoptotic amplification loop, which is the closest analog to a "second hit."

3. Phenotypes

Cutaneous phenotypes (hallmark; present in ~90–95% of patients; first sign in nearly all cases)

Skin lesions follow Blaschko's lines and progress through four classic, often overlapping stages with irregular onset/duration (Landy & Donnai major criterion) (Actas Dermo-Sifiliográficas review, PMID:30660327; Minić et al. update, PMID:23802866):

Stage Clinical description Typical timing Histopathology Suggested HPO
I – Vesicular/bullous Erythematous linear vesiculobullous/pustular eruption on limbs/trunk Birth to ~4 months (often present at birth or first 2 weeks) Eosinophilic spongiosis, intraepidermal eosinophil-filled vesicles, dyskeratotic keratinocytes HP:0025500 (Vesiculobullous rash) / HP:0008066
II – Verrucous Linear, warty, hyperkeratotic papules/plaques Weeks–months, overlapping with stage I Hyperkeratosis, acanthosis, papillomatosis, dyskeratosis HP:0000988 (Skin rash) / verrucous lesion terms
III – Hyperpigmented Swirled/marbled ("splash of paint") grey-brown hyperpigmentation along Blaschko lines, often NOT at sites of prior blistering Infancy through childhood; may be the presenting sign in older infants Abundant dermal melanophages with pigment incontinence (the eponymous finding) HP:0007441 (Reticulate hyperpigmentation) / HP:0001010 (Hyperpigmentation of the skin)
IV – Atrophic/hypopigmented Pale, hairless, atrophic, anhidrotic linear streaks/patches, often on the calves Adolescence–adulthood; may persist lifelong Epidermal atrophy, loss of rete ridges and adnexal structures, reduced basal melanocytes HP:0001010 / HP:0000953 (Hyperpigmented skin patches) / hypopigmentation terms

The vesicular stage carries a diagnostically important triad: characteristic Blaschko-linear vesicles + peripheral blood eosinophilia + histopathologic eosinophilic spongiosis — eosinophil counts of 5–79% (leukocytosis up to ~84,000/µL), peaking at 3–5 weeks of life, driven by NEMO-competent neighboring keratinocytes secreting eotaxin (PMC12569988 "Diagnostic Triad"; Medscape workup).

Extracutaneous phenotypes (minor criteria; frequency data drawn from the largest modern cohorts, principally the 2024 Danish nationwide study, PMID:39623400, and classic case series)

System Phenotype Frequency Onset Course HPO suggestion
Teeth Hypodontia/anodontia, delayed eruption, peg-shaped/conical teeth, microdontia, impacted teeth 17–34% (older series); 58.7% (2024 nationwide cohort) Deciduous and permanent dentition Stable HP:0000679 (Abnormal dentition), HP:0000692 (Hypodontia), HP:0000693 (Peg-shaped teeth)
Hair Scarring vertex alopecia, wiry/coarse/lusterless hair, sparse hair in early childhood 26–50% Infancy onward Often stable/permanent scarring HP:0004291 (Cicatricial alopecia), HP:0002212 (Scalp hair loss)
Nails Pitting, ridging, subungual hyperkeratosis, onycholysis, nail dystrophy (may mimic tumors) 7–40% (16% in 2024 cohort) Childhood Stable/chronic HP:0001817 (Toenail dystrophy) / HP:0004097 (Abnormality of the nail)
Eyes Retinal vascular anomalies (peripheral avascularity, neovascularization), retinal detachment, strabismus, cataract, optic atrophy, microphthalmia 22.6–35% (up to 77% in some referral cohorts) Neonatal–infancy for the sight-threatening retinal vasculopathy Progressive if untreated — the retinopathy is the leading cause of permanent disability HP:0000556 (Retinal detachment), HP:0007843 (Attenuation of retinal blood vessels), HP:0000486 (Strabismus), HP:0000518 (Cataract)
CNS Seizures, microcephaly, encephalopathy, motor/cognitive delay, hemiparesis, ischemic/hemorrhagic stroke ~30% (30.7% in the 2024 cohort); seizures ~20% Predominantly neonatal period (correlates with cerebrovascular injury severity) Can be monophasic (neonatal) or evolve to fixed deficits; occasional acquired lesions later HP:0001250 (Seizure), HP:0001300 (Encephalopathy), HP:0002119 (Ventriculomegaly), HP:0002315 (Headache)
Skeletal/other Nipple/breast anomalies (accessory nipples, hypoplastic breast), skeletal anomalies, short stature (rare) <10% Variable Stable HP:0006190 (Rudimentary supernumerary nipple)
Systemic laboratory Peripheral eosinophilia/leukocytosis (stage I–II) Common in neonatal period Neonatal, resolves Self-limited HP:0001880 (Eosinophilia)

Quality-of-life impact: Dermatologic manifestations largely attenuate over years and rarely cause lasting disability once past the scarring/pigmentary stages, but ocular disease persists lifelong and is the dominant driver of long-term QoL burden (progressive visual impairment, need for lifelong ophthalmologic surveillance) (Actas Dermo-Sifiliográficas). Neurodevelopmental sequelae from neonatal CNS injury (motor and cognitive impairment, and documented learning disabilities as a "fundamental hallmark" even without gross neuroimaging abnormality, per PMC3906222) are the other major long-term QoL determinant. No validated disease-specific QoL instrument was identified in the literature searched; generic pediatric QoL and visual-function instruments have been used in small cohorts.

4. Genetic / Molecular Information

Causal gene: IKBKG (NEMO), HGNC:5961, Xq28, encoding the ~48-kDa NF-κB essential modulator, the non-enzymatic regulatory/scaffolding subunit of the IKK complex.

Pathogenic variant spectrum: - Recurrent 11.7-kb deletion of exons 4–10 ("IKBKGdel") — accounts for ~65–80% of unrelated probands; a complete-loss-of-function null allele generated by NAHR between MER67B repeats flanking the deleted region (PMID:19603533). Because the genomic architecture at Xq28 is inherently unstable, this exact deletion recurs independently in unrelated families rather than representing a single ancestral founder allele. - Small indels, nonsense, and canonical splice-site variants distributed across the remaining coding exons — the second most common class, usually also null/loss-of-function. - Missense/hypomorphic variants — rare in classic IP; these more often produce the allelic disorder EDA-ID (Ectodermal Dysplasia and Immunodeficiency 1, OMIM #300291) in hemizygous males, with impaired but not abolished NF-κB signaling, hypogammaglobulinemia, poor polysaccharide antibody responses, and susceptibility to pyogenic/mycobacterial infection (PMID:26117626; PMID:28993958; PMC12221755, "Clinical relevance of loss-of-function mutations of NEMO/IKBKG"). Some hypomorphic alleles produce combined IP + immunodeficiency + immune thrombocytopenia phenotypes, illustrating an allelic severity continuum from null (male-lethal/classic IP in mosaic or XXY males) → hypomorphic (EDA-ID, viable males) → complete loss with somatic mosaicism (mild/atypical IP in males). - Larger microdeletions/microduplications at Xq28 encompassing IKBKG and neighboring genes can also generate the exon 4–10 deletion allele de novo through a complex rearrangement mechanism, and can produce contiguous-gene phenotypes.

Variant classification / interpretation: ACMG/AMP pathogenic and likely-pathogenic classifications predominate in ClinVar for the recurrent deletion and truncating variants; missense VUS interpretation is complicated by segmental duplication of IKBKG (a pseudogene, ΔIKBKG, lies distally and complicates short-read NGS/CNV calling) — long-read sequencing is increasingly recommended for unambiguous resolution of the exon 4–10 deletion and to distinguish it from the paralogous pseudogene sequence (npj Genomic Medicine 2024; PMC11838753, "Long-Read Sequencing is Required for Precision Diagnosis").

Population/allele frequency: Because the pathogenic deletion sits in a segmentally duplicated, structurally unstable region, it is essentially absent from gnomAD/1000 Genomes/ExAC as a "population variant" — it behaves as a recurrent de novo/rare familial lesion rather than a polymorphism, consistent with strong purifying selection against male-lethal null alleles.

Somatic vs. germline origin: IP is a germline (constitutional) X-linked disorder in females; however, the phenotype itself is a manifestation of mosaicism (X-inactivation mosaicism is obligatory for female survival), and rare surviving affected males owe survival to true post-zygotic somatic mosaicism for the mutation itself (distinct from XCI mosaicism) (PMID:11673821).

Functional consequence: Loss of function — NEMO/IKKγ is required for IKK-complex-mediated phosphorylation and degradation of IκB, the step that liberates NF-κB dimers (RelA/p65–p50) to translocate to the nucleus. Loss of NEMO function abolishes canonical NF-κB activation in response to TNF-family cytokines, IL-1, and other pro-inflammatory/pro-survival stimuli, converting a normally pro-survival signal into a pro-apoptotic one in affected cells (Smahi et al./Courtois review, PMID:12351572, "The NF-κB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes").

Modifier genes: No validated disease-modifying loci are established beyond X-inactivation ratio itself, which functions as the principal "modifier" of phenotypic severity in females.

Epigenetics: The central epigenetic phenomenon in IP is extreme, non-random (skewed) X-chromosome inactivation, arising secondarily from selective apoptotic elimination of cells expressing the mutant allele rather than from a primary epigenetic lesion; this is well documented in blood leukocytes and can be used diagnostically to identify carrier relatives when the causal variant cannot itself be found (PMC7767561).

Chromosomal abnormalities: 47,XXY (Klinefelter syndrome) is a documented mechanism enabling survival of hemizygous null-mutation males, via provision of a second X allele subject to skewed inactivation, analogous to the female mechanism.

Suggested ontology terms: Gene — HGNC:5961 (IKBKG); GO:0007249 (I-κB kinase/NF-κB signaling); GO:0051092 (positive regulation of NF-κB transcription factor activity); GO:0008384 (IκB kinase activity); GO:0006915 (apoptotic process).

5. Environmental Information

IP has no established environmental, lifestyle, or infectious causal contribution to disease onset — the primary lesion is a germline/mosaic IKBKG variant. There is no CTD/TOXNET association implicating toxins, and no infectious trigger for the disease itself. The main environmental interaction of clinical relevance is iatrogenic/incidental: (1) neonatal vesicular-stage lesions are frequently mistaken for and must be differentiated from neonatal herpes simplex virus infection (PMC6020482, "Incontinentia Pigmenti Misdiagnosed as Neonatal HSV Infection") — importantly, HSV and IP can also coexist, so HSV must always be actively excluded rather than assumed to be the diagnosis; and (2) case reports of complications following treatment interventions (e.g., necrotizing enterocolitis following intravitreal bevacizumab in an infant with IP) reflect treatment-related, not disease-causal, environmental exposure (PMC6792241). No infectious agent, occupational exposure, or lifestyle factor is described as a disease trigger in the reviewed literature.

6. Mechanism / Pathophysiology

Causal chain (trigger → clinical manifestation):

  1. Molecular trigger: Heterozygous loss-of-function IKBKG variant (most commonly the exon 4–10 deletion) abolishes NEMO/IKKγ scaffolding function within the IKK complex (IKKα/IKKβ/NEMO), which is normally required for K63-linked polyubiquitin-dependent activation of the complex downstream of TNFR1, IL-1R/TLR, and CD40 signaling (PMID:12351572).
  2. Cellular consequence — loss of NF-κB-mediated cytoprotection: Without functional NEMO, IκB is not degraded, NF-κB (RelA/p65) cannot translocate to the nucleus, and NF-κB target anti-apoptotic genes (e.g., BCL2, BCL-XL, cFLIP, cIAP1/2) are not induced. NEMO-deficient keratinocytes therefore become exquisitely sensitive to TNF-α-induced apoptosis/necrosis — a signal that in normal cells is pro-survival becomes lethal in NEMO-null cells.
  3. Amplification loop (the key mechanistic feature of IP): Neighboring NEMO-competent keratinocytes (the cells that retained the wild-type X as the active allele) respond normally to inflammatory stimuli by activating NF-κB and secreting chemokines/cytokines — eotaxin, RANTES, MCP-1, IL-1, TNF-α, IFN-γ, lymphotactin — which (a) recruit eosinophils and other inflammatory cells (explaining the pathognomonic eosinophilic spongiosis and peripheral eosinophilia of stage I/II) and (b) further amplify TNF-driven apoptosis specifically in the neighboring NEMO-deficient cells (Frontiers Pediatr. 2022, PMC9485571; Medscape pathophysiology).
  4. Clonal resolution: Progressive apoptotic elimination of NEMO-deficient keratinocyte clones, coupled with proliferative replacement by NEMO-expressing keratinocytes, produces the temporal evolution of skin stages — inflammatory/vesicular (active killing + inflammation) → verrucous (reactive hyperproliferation) → hyperpigmented (dermal macrophage/melanophage clearance of released melanin — "incontinence of pigment," the eponymous histologic finding) → atrophic/hypopigmented (end-stage tissue with reduced adnexal structures and melanocyte density after clonal loss) (PMID:24937825).
  5. Vascular mechanism (retina/CNS): The same NEMO-dependent apoptosis-vs-survival logic operates in vascular endothelium: mosaic loss of NF-κB protection in endothelial/vascular precursor clones is proposed to underlie the occlusive retinal and cerebral microvasculopathy — avascular peripheral retina, neovascularization, and in the CNS, small-vessel occlusion, ischemic/hemorrhagic infarction, and cerebral arteriopathy — that account for the sight- and life-threatening complications of IP (Cerebral Arteriopathy report, PMID:26706482; PMC3576363, systematic review of CNS anomalies).
  6. A validated "reverse experiment": A case report of IP recrudescence during TNF/NF-κB blockade in an inflammatory malignancy context provides a natural experiment supporting the causal centrality of NF-κB blockade to IP pathophysiology in vivo in humans (PMC10520490).

Upstream vs. downstream: Upstream = germline/mosaic IKBKG genotype and X-inactivation pattern (fixed, not modifiable). Downstream = TNF-family-cytokine-triggered, cell-autonomous keratinocyte/endothelial apoptosis, a cell-non-autonomous inflammatory amplification loop, and tissue-level consequences (skin staging, retinal vaso-occlusion, cerebral small-vessel injury).

Cell types involved: Epidermal keratinocyte (basal and suprabasal), dermal melanophage/macrophage, eosinophil, vascular endothelial cell (retinal and cerebral), and (in the allelic EDA-ID spectrum) lymphocytes/monocytes.

Molecular profiling: No large-scale transcriptomic/proteomic/metabolomic datasets specific to IP skin or blood were identified in this search (reflecting the rarity of the disease and lack of GEO/PRIDE/MetaboLights-deposited disease-specific omics datasets); mechanistic insight instead derives predominantly from the Ikbkg-null/keratinocyte-conditional mouse model (below) and from targeted cytokine/histopathology studies in humans.

Suggested ontology terms: - GO Biological Process: GO:0007249 (I-κB kinase/NF-κB signaling), GO:0006915 (apoptotic process), GO:0034612 (response to tumor necrosis factor), GO:0006954 (inflammatory response), GO:0001525 (angiogenesis, for the retinal vasculopathy). - GO Molecular Function: GO:0008384 (IκB kinase activity). - Cell Ontology: CL:0000312 (keratinocyte), CL:0000158 (club cell — N/A; use CL:0000148 melanocyte), CL:0000771 (eosinophil), CL:0000115 (endothelial cell). - CHEBI: CHEBI:60485 (tumor necrosis factor) — for the causal cytokine.

7. Anatomical Structures Affected

Organ level: - Primary: Skin/integument (epidermis, dermis, hair follicles, nails), eye (retina primarily; also lens, optic nerve), central nervous system (brain parenchyma and cerebral vasculature). - Secondary/complication-driven: Retinal detachment as a complication of untreated retinal vasculopathy; secondary infections of denuded/bullous skin; dental arch/palate anomalies as a developmental consequence of ectodermal involvement. - Body systems: Integumentary, ophthalmologic, neurologic, dental/craniofacial, and (in the allelic EDA-ID spectrum) immune system.

Tissue/cell level: - Epidermis (keratinocytes, CL:0000312), melanocytes (CL:0000148) and their pigment-laden dermal macrophage counterparts (melanophages), hair follicle (pilosebaceous unit), nail matrix, retinal vascular endothelium (CL:0000115) and retinal pigment epithelium, cerebral small-vessel endothelium, cerebral cortical/subcortical neurons and white matter.

Subcellular level: The core molecular lesion operates through cytoplasmic IKK-complex signaling (GO:0008385 IκB kinase complex) leading to nuclear translocation of NF-κB (nucleus, GO:0005634) and mitochondrial-pathway apoptosis (GO:0005739) in affected cells.

Localization (UBERON): - UBERON:0002097 (skin epidermis) — Blaschko-linear distribution, classically trunk and extremities. - UBERON:0000966 (retina) — peripheral retinal avascular zone with a sharp vascular/avascular demarcation, most often temporal. - UBERON:0000955 (brain) — periventricular white matter, corpus callosum, basal ganglia/thalami, and small-vessel cerebral parenchyma. - UBERON:0001091 (tooth) — dental lamina/enamel organ.

Lateralization: Cutaneous, and often CNS, lesions are classically unilateral or strikingly asymmetric, reflecting the mosaic (clonal, Blaschko-line) nature of the disorder — e.g., documented unilateral cerebral atrophy as a distinct, non-acute neuroimaging phenotype of IP (PMID:30090155). Retinal vasculopathy can be unilateral or bilateral and asymmetric in severity.

8. Temporal Development

Onset: Congenital/neonatal for the defining cutaneous stage I lesions (present at birth or within the first 2 weeks in the majority; occasionally delayed to weeks 3–4). CNS and retinal complications, when they occur, present predominantly in the neonatal period as well, reflecting a shared early-life window of vulnerability tied to active mosaic apoptotic clearance and vascular development. Onset pattern for the acute complications (seizures, stroke-like injury) is typically acute/subacute; the skin disease itself evolves in an insidious, staged fashion.

Progression / disease course: - Skin: Classic stage-wise progression (I→II→III→IV) though stages "may overlap" and their "sequence is irregular" and duration variable (PMID:24937825). The dermatologic phenotype is generally self-attenuating over years — stage IV (atrophic/hypopigmented) lesions may persist into adulthood but are cosmetically stable rather than progressive. - Retina: Vaso-occlusive disease can be rapidly progressive in untreated infants, evolving from peripheral avascularity to neovascularization to tractional retinal detachment within weeks to months if unmonitored — this is the principal reason for close, serial ophthalmologic screening in the first months of life. - CNS: Acute neonatal encephalopathy/seizures/stroke represent a discrete early "critical period"; some neuroimaging abnormalities (e.g., diffusion restriction) have been reported as nearly completely reversible on follow-up imaging in some cases (AJNR PMC report), while others (unilateral cerebral atrophy) are fixed/progressive-appearing structural sequelae. - Disease duration: Chronic, lifelong condition overall, but with a bimodal severity pattern — an early (neonatal/infancy) period of highest risk for irreversible ocular and neurologic injury, followed by a chronic stable phase in surviving patients without early complications, in whom life expectancy and general health are normal (StoryMD/clinical summaries; Orphanet).

Patterns: - Remission: The cutaneous eruption remits spontaneously (clonal clearance mechanism, not treatment-induced) as NEMO-deficient keratinocyte clones are eliminated. - Critical period: The first weeks to months of life constitute the critical window for both (a) diagnostic recognition (vesicular stage + eosinophilia triad) and (b) prevention of irreversible retinal/CNS injury through early ophthalmologic and neurologic screening — repeatedly emphasized across the ophthalmology literature as the key modifiable determinant of long-term outcome (Orphanet J Rare Dis, "Early management of sight threatening retinopathy in incontinentia pigmenti," PMC/Springer).

9. Inheritance and Population

Epidemiology: - Historically cited birth prevalence: 0.7 per 100,000 births (Orphanet, 2013 estimate); more recent series report 1.2 per 100,000 ([search synthesis]); the most recent, methodologically robust nationwide Danish study (2024) found a birth prevalence of 2.37 per 100,000 live births (95% CI 1.74–3.25), or ~1 in 42,194 — roughly twice earlier estimates, likely reflecting improved case ascertainment (PMID:39623400). Orphanet also cites a birth prevalence of approximately 1 in 143,000 in some estimates and a period prevalence in the US of 0.88 per 100,000. Older birth-surveillance-system estimates were as low as 0.6–0.7 per 1,000,000, reflecting substantial historical under-ascertainment. - IP is universally described as rare, with wide variance across studies attributable to differing case-finding methodology (clinical vs. registry vs. genetically confirmed cohorts).

Inheritance pattern: X-linked dominant, male-lethal for the common null allele (in utero loss of hemizygous null male conceptuses). GeneReviews states the expected live-birth ratio for offspring of an affected (heterozygous) mother is approximately 1/3 unaffected female : 1/3 affected female : 1/3 unaffected male, with affected male conceptuses largely lost to miscarriage (GeneReviews NBK1472). Sex ratio in liveborn, clinically recognized patients is reported as approximately 20 females : 1 male (rare surviving males owe this to somatic mosaicism, Klinefelter 47,XXY, or hypomorphic alleles, as above).

Penetrance/expressivity: Effectively complete penetrance for cutaneous disease in liveborn heterozygous females, but markedly variable expressivity for extracutaneous (dental, ocular, hair, nail, CNS) manifestations — a direct consequence of stochastic X-inactivation ratios between individuals.

Genetic anticipation: Not described — IP is not a repeat-expansion disorder.

Germline mosaicism: Documented and clinically important — a molecularly normal (or apparently unaffected/mildly affected) mother can have germline (gonadal) mosaicism for the IKBKG variant, producing familial recurrence despite an apparently de novo variant in the index case, a scenario specifically studied for genetic-counseling implications (Steffann et al. 2024, AJMG-A).

Founder effects: The exon 4–10 deletion is recurrent (arising independently in multiple unrelated families via NAHR) rather than a single ancestral founder allele — an important distinction from typical founder-mutation disorders.

Consanguinity: Not a relevant risk factor, given the X-linked dominant, largely de novo mutational mechanism.

Carrier frequency: Not meaningfully defined in the classic sense (unlike recessive carrier screening), given the predominance of de novo mutation and male lethality; population allele frequency for the pathogenic deletion is essentially unobservable in gnomAD-type reference cohorts due to strong negative selection and segmental-duplication artifacts.

Population demographics: No strong ethnic or geographic clustering has been reported; IP occurs worldwide across populations. Age distribution of affected individuals in registries spans neonates through adults, consistent with normal life expectancy in patients without severe neonatal complications. Sex ratio (~20:1 female:male) is the most consistent demographic feature.

10. Diagnostics

Clinical diagnostic criteria: Landy and Donnai (1993) established major criteria (any of the four Blaschko-linear skin stages) and minor criteria (dental, ocular, CNS, hair, nail, palate, breast/nipple anomalies; history of multiple male miscarriages; characteristic histopathology). Minić et al. (2014) revised/updated these criteria to incorporate molecular genetics, adding positive first-degree family history and a pathogenic IKBKG/NEMO variant as additional diagnostic criteria alongside the updated major/minor clinical criteria (PMID:23802866).

Laboratory tests: - Complete blood count with differential — peripheral eosinophilia/leukocytosis is a key supportive finding during stages I–II (LOINC panels for CBC/differential apply; no IP-specific biomarker assay exists). - Skin biopsy/histopathology by stage (eosinophilic spongiosis → hyperkeratosis/dyskeratosis → dermal melanophages/pigment incontinence → epidermal atrophy) — SNOMED CT histopathology terms for spongiotic dermatitis, pigment incontinence.

Genetic testing (primary confirmatory modality): - Recommended approach (GeneReviews): Targeted testing for the recurrent exon 4–10 deletion first (accounts for the majority of cases), typically by MLPA, long-range PCR, or CNV-sensitive assays, given that standard short-read NGS/exome sequencing can miss or misassign this deletion due to the IKBKG pseudogene (ΔIKBKG) segmental duplication. - If the recurrent deletion is not found, sequence analysis of the full IKBKG coding region (single-gene sequencing or NF-κB/immunodeficiency-focused gene panels) is the next step. - Long-read sequencing is increasingly advocated as the most precise, single-assay strategy to resolve the deletion breakpoints and rule out pseudogene interference, and has been proposed as an efficient molecular testing strategy specifically for IP (npj Genomic Medicine 2024; PMC11838753). - Chromosomal microarray/karyotype: Karyotyping is relevant specifically in surviving affected males to test for 47,XXY (Klinefelter) as a survival mechanism. - X-inactivation studies in peripheral blood are a useful adjunct, especially to identify carrier female relatives when the causative variant cannot be confidently identified in the proband (PMC7767561). - Prenatal/preimplantation testing: Both prenatal diagnosis (in known-familial pathogenic variants) and preimplantation genetic testing are available and used for reproductive planning given the high recurrence risk to offspring of affected mothers.

Imaging: - Ophthalmologic: Fluorescein angiography (FA) is central to detecting peripheral retinal avascularity and neovascularization before clinically apparent detachment. - Neuroimaging: Brain MRI/MR angiography and diffusion-weighted imaging for neonates with seizures/encephalopathy — findings include small-vessel occlusion, ischemic/hemorrhagic changes, corpus callosum hypoplasia, ventriculomegaly, periventricular white matter disease, polymicrogyria, and neuronal heterotopia (MedLink Neurology summary; PMC3576363).

Differential diagnosis (stage-specific, per Medscape/EyeWiki synthesis): - Stage I (vesicular): Neonatal HSV, varicella, epidermolysis bullosa, bullous pemphigoid/impetigo, dermatitis herpetiformis, bullous SLE, linear IgA bullous dermatosis, pemphigus vulgaris, bullous mastocytosis — neonatal HSV must always be actively excluded, and the two conditions can coexist (PMC6020482). - Stage II (verrucous): Verruca vulgaris, linear epidermal nevus. - Stage III (hyperpigmented): Linear and whorled nevoid hypomelanosis, dermatopathia pigmentosa reticularis, Naegeli-Franceschetti-Jadassohn syndrome, X-linked dominant chondrodysplasia punctata, other pigment mosaicism disorders. - Stage IV (atrophic/hypopigmented): Hypomelanosis of Ito (key distinguishing feature: never has preceding bullous or verrucous lesions).

Screening: No population-based newborn or carrier screening program exists for IP (it is too rare and typically clinically apparent), but targeted screening of at-risk relatives (X-inactivation studies, targeted variant testing) is standard once a proband is identified, given the counseling implications of germline mosaicism.

11. Outcome / Prognosis

Survival/mortality: For females without significant neonatal CNS or systemic complications, life expectancy is normal. Mortality in IP is essentially confined to (a) in utero loss of hemizygous null male conceptuses (not counted in liveborn mortality statistics) and (b) rare severe neonatal complications (e.g., overwhelming cerebral vascular injury) in liveborn patients. No IP-specific 5-/10-year survival statistic (of the cancer-registry type) applies, as IP is not typically fatal in surviving liveborn patients.

Morbidity/function: - ~20% of patients develop neurologic sequelae ranging from mild to severe (motor deficits, epilepsy, intellectual disability); notably, learning disabilities have been specifically flagged as a fundamental, under-recognized hallmark of IP even in patients without overt structural brain lesions (PMC3906222, "Learning Disabilities Are a Fundamental Hallmark of the Disease"). - Ocular involvement (22.6–77% depending on cohort/referral bias) is the principal source of persistent, lifelong QoL impact, given that retinal vasculopathy, once established, is not reversible and dermatologic disease is not. - Dental, nail, and hair anomalies are largely cosmetic/functional-minor and stable rather than progressive.

Disease course/complications: Principal complications are tractional retinal detachment (from untreated peripheral retinal vaso-occlusion/neovascularization), neonatal seizures/encephalopathy, and ischemic/hemorrhagic cerebral injury. Secondary skin infection during the bullous stage is a lesser but real risk.

Prognostic factors: The presence and severity of neonatal CNS involvement and early retinal vasculopathy are the dominant prognostic determinants for long-term disability; patients without these neonatal complications generally have normal physical and cognitive development and normal life expectancy. Early ophthalmologic screening/intervention is repeatedly identified in the literature as the single most impactful modifiable prognostic lever (Orphanet J Rare Dis, "Early management of sight threatening retinopathy").

12. Treatment

There is no disease-modifying or curative therapy for IP — management is entirely organ-specific, supportive, and surveillance-driven, reflecting the mosaic/self-limited nature of the underlying cellular lesion once the vulnerable neonatal window has passed.

Dermatologic (supportive care): - Gentle wound care for bullous lesions, avoidance of secondary infection; no specific pharmacotherapy alters the natural staged evolution. MAXO:0000950 (supportive care).

Ophthalmologic (the best-defined interventional area): - Serial ophthalmologic examination with fluorescein angiography in the neonatal period/infancy to detect peripheral retinal avascularity before neovascularization/detachment develops — the standard of care recommendation across sources. - Laser photocoagulation (parameters largely extrapolated from retinopathy-of-prematurity practice) of avascular retina is the primary treatment for progressive retinal neovascularization (MAXO term: laser therapy; NCIT procedure term applicable). - Anti-VEGF therapy (intravitreal bevacizumab): used as an adjunct, not first-line, given theoretical concern about systemic VEGF suppression in a multisystem vascular disorder (with documented case reports of adverse events, e.g., necrotizing enterocolitis post-injection) and given that IP is also associated with cerebrovascular disease/stroke risk — most authors recommend reserving anti-VEGF for severe/atypical cases with posterior neovascularization or media opacity precluding laser, as a second-line option rather than routine therapy; no formal treatment consensus exists (PMID:30768227; PMID:30982292; Retina Today 2026; PMC6792241). - Surgical retinal detachment repair (scleral buckle/vitrectomy) for established tractional detachment.

Neurologic: Standard antiepileptic pharmacotherapy for seizures; supportive/rehabilitative care (physical, occupational, speech therapy — MAXO:0000011, MAXO:0001351, MAXO:0000930) for motor/developmental delay.

Dental: Restorative/prosthodontic management of hypodontia/microdontia/peg-shaped teeth (implants, crowns, orthodontic planning) — a described multidisciplinary oral rehabilitation approach exists in the literature (PMC10529459); NCIT:C15329 (surgical/dental procedure), MAXO:0000004 for surgical correction.

Genetic counseling: MAXO:0000079 (genetic counseling) is central to management — addressing the ~50% transmission risk from an affected mother (with the caveat of in utero loss of affected male conceptuses), the possibility of germline mosaicism in an apparently unaffected mother, and reproductive options (prenatal diagnosis, preimplantation genetic testing).

Experimental/advanced therapeutics: No gene therapy, cell therapy, RNA-based therapy, or targeted molecular therapy directed at IKBKG/NF-κB restoration was identified as being in clinical development for IP in this search — the mosaic, self-clearing nature of the cutaneous disease and the segmental/organ-specific management paradigm for eye/CNS complications likely explain the absence of a systemic disease-modifying drug pipeline. No IP-specific NCT trials for a curative/disease-modifying agent were surfaced in this search; ophthalmology practice largely borrows ROP-derived treatment protocols and evidence rather than IP-dedicated trials.

Treatment outcomes: No large systematic response-rate data exist for anti-VEGF vs. laser specifically in IP given its rarity; case-series evidence supports revascularization following combined bevacizumab + laser in bilateral retinal vascular occlusion (PMID:30768227).

Treatment strategy/algorithm: Multidisciplinary care pathway spanning neonatology, pediatric dermatology, pediatric ophthalmology, pediatric neurology, dentistry, and clinical genetics, with the critical early-infancy period for ophthalmologic/neurologic surveillance being the crux of the management algorithm.

13. Prevention

Primary prevention: Not applicable in the classic sense (no environmental exposure to avoid); the only "primary prevention" lever is reproductive, i.e., avoiding transmission through informed reproductive choices after genetic counseling (prenatal diagnosis, preimplantation genetic testing) in families with a known pathogenic variant.

Secondary prevention (the most clinically important prevention modality for IP): Early detection of retinal vasculopathy via scheduled ophthalmologic examination with fluorescein angiography in the neonatal period and infancy, enabling timely laser therapy before neovascularization progresses to tractional retinal detachment — repeatedly emphasized in the ophthalmology literature as the single highest-yield preventive intervention in this disease (Orphanet J Rare Dis). Analogous early neurologic surveillance (clinical exam ± neuroimaging in symptomatic neonates) aims to identify and manage acute cerebrovascular injury promptly, though there is no specific prophylactic pharmacotherapy shown to prevent the cerebral vasculopathy itself.

Genetic/prenatal screening: Genetic counseling with prenatal or preimplantation genetic testing is offered to at-risk pregnancies once a familial pathogenic variant is known; X-inactivation studies can help risk-stratify apparently unaffected female relatives.

Immunization: Not applicable — IP is not an infectious or vaccine-preventable disease (though patients with the allelic EDA-ID phenotype from hypomorphic variants may warrant tailored immunization/infection-prophylaxis strategies given their underlying immunodeficiency — a distinct clinical entity from classic IP).

Behavioral/public health/prophylaxis: No behavioral, dietary, or public-health-level prevention measures apply to this monogenic disorder; the entire preventive strategy for morbidity reduction centers on early clinical surveillance and reproductive genetic counseling rather than exposure avoidance.

14. Other Species / Natural Disease

Taxonomy: No naturally occurring IP-equivalent disease in non-human species (companion animals, livestock, or wildlife) was identified in this search — this is consistent with the disease being a rare, human-specific presentation of a mosaic X-linked lethal mutation, and no OMIA (Online Mendelian Inheritance in Animals) entry for a natural IP phenocopy was found. (Note: a distinct EDA-related hypohidrotic ectodermal dysplasia — caused by a different gene, EDA, not IKBKG — does occur naturally in Fleckvieh cattle as a collagen-triple-helix missense variant, but this is a different disease/gene and should not be conflated with IP; PMC10815684.)

Orthologous gene: Ikbkg/NEMO is highly conserved in mammals (mouse Ikbkg, NCBI Gene; ortholog used extensively in the engineered mouse models below), but no spontaneous/natural disease-causing Ikbkg mutation has been reported in any non-human species.

Comparative biology: The evolutionary conservation of the NF-κB/IKK pathway across vertebrates underlies the strong construct and face validity of engineered rodent models (below) despite the absence of a naturally occurring animal disease.

15. Model Organisms

Primary genetic model — the Ikbkg/NEMO-deficient mouse (the well-established IP model): - Germline Ikbkg-null mice: Disruption of the X-linked Ikbkg gene produces male embryonic lethality, completely abolishes NF-κB activation by pro-inflammatory cytokines, and impairs lymphocyte generation/persistence — directly recapitulating the human male-lethal pattern (Rudolph et al., Molecular Cell 2000, PMID:10911992). - Heterozygous female mice develop patchy skin lesions with massive granulocyte infiltration, keratinocyte hyperproliferation, and increased keratinocyte apoptosis; affected animals show severe growth retardation and early mortality, but surviving mice recover almost completely as NEMO-deficient keratinocyte clones are cleared and replaced — this is a striking phenotypic and mechanistic parallel to the self-limited human cutaneous disease course (Molecular Cell, "NEMO/IKKγ-Deficient Mice Model Incontinentia Pigmenti"). - Keratinocyte-restricted conditional Ikbkg deletion (constitutive or inducible in adult skin) is sufficient to cause inflammatory skin lesions on its own, formally establishing the NEMO-deficient keratinocyte as the initiating cell type that triggers IP-like skin pathology, and additionally shows a strict requirement for TNF signaling in lesion development (crossing onto a TNF-receptor-deficient background rescues the phenotype) (Nenci et al., PMID:16399796). - Related mouse genetic work on IKKα (a downstream/interacting kinase) has additionally revealed unexpected, partially distinct roles in skin development and skin carcinogenesis, providing comparative mechanistic context for the IKK-complex/skin biology relationship (PMC3730312).

Model characteristics: - Phenotype recapitulation: Excellent for the core disease logic — male lethality, mosaic-dependent female skin disease, granulocytic/eosinophilic-type inflammation, keratinocyte apoptosis, and spontaneous clonal resolution are all reproduced. - Model limitations: The mouse model is a construct-driven, engineered knockout (not a spontaneous disease), and does not on its own model the human ocular retinal vasculopathy or CNS stroke/encephalopathy phenotypes as thoroughly characterized systems — those complications are documented primarily from human case series/imaging studies rather than from dedicated mouse retinal/cerebrovascular IP-model literature identified in this search. - Research applications: The keratinocyte-specific conditional model in particular has been used to dissect the cell-autonomous vs. non-cell-autonomous (paracrine/TNF-dependent) contributions to lesion pathogenesis, directly informing the human "amplification loop" mechanistic model described in Section 6.

Resources: Mouse Genome Informatics (MGI) carries the Ikbkg knockout and conditional alleles used in these studies; no zebrafish, Drosophila, C. elegans, or iPSC/organoid IP-specific disease models were identified in this search, though iPSC-based mosaic keratinocyte modeling would be a plausible unexplored avenue given the human disease's cell-autonomous logic.

Summary of Key Suggested Ontology Terms for KB Curation

  • Gene: hgnc:5961 (IKBKG)
  • Disease: MONDO:0010631; OMIM:308300; ORPHA:464; allelic disorder OMIM:300291 (EDA-ID1)
  • HPO (selected): HP:0025500/HP:0008066 (vesiculobullous skin lesions), HP:0007441 (reticulate hyperpigmentation), HP:0000692 (hypodontia), HP:0000693 (peg-shaped teeth), HP:0004291 (cicatricial alopecia), HP:0001817 (nail dystrophy), HP:0000556 (retinal detachment), HP:0007843 (retinal vascular attenuation), HP:0001250 (seizure), HP:0001300 (encephalopathy), HP:0001880 (eosinophilia), HP:0010984 (digenic — N/A here; standard X-linked dominant term instead)
  • GO: GO:0007249 (I-κB kinase/NF-κB signaling), GO:0008384 (IκB kinase activity), GO:0051092 (positive regulation of NF-κB transcription factor activity), GO:0006915 (apoptotic process), GO:0034612 (response to TNF), GO:0001525 (angiogenesis)
  • CL: CL:0000312 (keratinocyte), CL:0000148 (melanocyte), CL:0000771 (eosinophil), CL:0000115 (endothelial cell)
  • UBERON: UBERON:0002097 (epidermis), UBERON:0000966 (retina), UBERON:0000955 (brain), UBERON:0001091 (tooth)
  • CHEBI: CHEBI:60485 (TNF, as a signaling ligand context) — treatments largely procedural (laser, anti-VEGF antibody: bevacizumab, CHEBI:64085)
  • MAXO: MAXO:0000079 (genetic counseling), MAXO:0000014 (laser/radiation-adjacent procedure; more precisely an NCIT ophthalmic laser procedure term), MAXO:0000950 (supportive care), MAXO:0000011 (physical therapy)

Sources